Two B7-H3-directed antibody-drug conjugates delivered overall survival primary-endpoint wins in China-based phase III trials for relapsed small-cell lung cancer, reinforcing the clinical momentum behind the B7-H3 ADC class. MediLink’s tambotatug pelitecan (tam-peli; YL-201; Tam-Peli) met the overall survival endpoint versus topotecan in the TAISHAN-302 study, reducing the risk of death by 54% with a median OS of 13.3 months versus 9.4 months. In a separate China trial, risvutatug rezetecan (ris-rez; Artemis-008) also reportedly hit the overall survival endpoint with the same 0.46 hazard ratio, according to related reporting. The parallel findings add weight to the class-level viability of B7-H3 targeting in a setting with limited post-first-line options. The results were discussed in the context of IASLC 2026 World Conference on Lung Cancer, where the data package can influence how sponsors position confirmatory global studies. For biotech stakeholders, the main signal is not just response rates but survival hazard ratio consistency across programs—an important evidentiary benchmark for ADC developers seeking first-line expansion.